Peptide therapy menus decoded: BPC-157, CJC-1295, ipamorelin, and GHK-Cu

“Peptide therapy” is a menu category, not a diagnosis or a single treatment. Peptides are short chains of amino acids, but products sold under that umbrella can have different targets, routes, human evidence, and regulatory status. A clinic listing BPC-157, CJC-1295, ipamorelin, or GHK-Cu should be able to explain each one separately.

The central distinction is simple: being a naturally occurring signal, a research subject, or a substance a pharmacy can physically prepare is not the same as being an FDA-approved drug for the proposed use.

Four names, four separate files

Avoid transferring a claim from one row to another. A topical copper-peptide cosmetic does not establish the safety of injectable GHK-Cu. A laboratory or animal study of BPC-157 does not establish a human recovery outcome. And evidence about an approved peptide drug does not validate an unapproved peptide because both are peptides.

Approval and compounding are different questions

An FDA-approved drug has a reviewed application, defined manufacturing controls, labeling, and approved indications. A compounded drug is prepared for a patient or supplied under one of the federal compounding frameworks and does not undergo FDA premarket review for safety, effectiveness, and quality.⁴

For a bulk substance used in 503A compounding, federal conditions look to an applicable USP or NF monograph, whether the substance is a component of an approved drug, or whether it appears on the 503A bulks list. FDA’s Tailor Made warning letter explains those alternatives and describes products using CJC-1295, ipamorelin, BPC-157, and GHK-Cu that the agency said did not qualify for the cited 503A exemptions.³

In July 2026, FDA’s advisory committee considered BPC-157-related substances for possible inclusion on the 503A bulks list.² An advisory-committee meeting, nomination, or pending evaluation is not approval and should not be presented as one.

FDA’s safety-risk list is route specific

FDA says compounded BPC-157 may pose immunogenicity risks and presents challenges around peptide impurities and active-ingredient characterization; it also says it has limited safety information for proposed routes.¹ For injectable GHK-Cu, FDA identifies potential aggregation, peptide-related impurities, immunogenicity, and limited human data. For ipamorelin acetate, it describes similar characterization concerns and limited safety information for certain injectable routes.¹

This is not proof that every exposure causes harm. It is an explanation of why a generic assurance such as “pharmaceutical grade” is insufficient. The clinic and compounder should identify the material, testing, route, and legal basis precisely.

Evidence needs to match the promise

For each promised outcome, ask for controlled human studies of the same substance, molecular form, route, dose, duration, and population. Then identify whether the endpoint was clinically meaningful: less pain, faster return to function, measured hair density, or another defined result—not only a laboratory marker.

If the response is a stack of mechanistic diagrams, animal studies, testimonials, and papers about a different peptide, the evidence has not yet reached the claim. That does not require a suspicious posture; it simply keeps an exploratory therapy from being described as established.

Eight questions for a peptide consultation

1. What condition or goal is being evaluated? A precise indication makes the evidence and monitoring questions possible.
2. What exact molecule and form is prescribed? Record salt, acetate, free-base, complex, and any combination rather than only the short menu name.
3. Is a drug approved for this use? Ask for the FDA record and indication if approval is claimed.
4. If compounded, what condition permits it? Identify the 503A or 503B source and the basis for using that bulk substance and formulation.
5. What human evidence matches the route? Separate oral, topical, subcutaneous, and intravenous evidence.
6. How are identity and impurities tested? Ask what the finished product's documentation establishes, not only what the API supplier claims.
7. Who monitors the treatment? Name the prescriber, follow-up schedule, measurements, stop criteria, and response plan.
8. What is the total commitment? Include consultation, laboratory work, supplies, recurring doses, shipping, and what happens when treatment ends.

A practical decision framework

Laboratory monitoring should follow the proposed mechanism and individual risk, not a universal “peptide panel.” Ask what is measured before treatment, what change would alter the dose, what threshold would stop treatment, and whether the lab is assessing benefit, adverse effect, or both. A biomarker moving in the intended direction does not by itself establish the promised functional result, so keep the clinical endpoint visible too.

Advertising bundles can blur accountability. If one company markets the program, another conducts telehealth, and a third compounds and ships the product, write down all three legal names and the state where each operates. Confirm who holds the medical record, who answers an urgent question, and who replaces or investigates a questionable vial. A seamless checkout should still lead to a traceable care and supply chain.

Take the menu apart one peptide at a time. Match the exact molecule and route to the proposed outcome, current approval or compounding basis, human evidence, source controls, and monitoring plan. Treomark’s peptide-therapy search can locate providers publishing the category; the consultation must still establish which substance, product, clinician, and evidence sit behind it.